PMID- 20682675
OWN - NLM
STAT- MEDLINE
DCOM- 20110214
LR  - 20220331
IS  - 1499-2752 (Electronic)
IS  - 0315-162X (Linking)
VI  - 37
IP  - 10
DP  - 2010 Oct
TI  - Levels of transforming growth factor-beta are low in systemic lupus erythematosus 
      patients with active disease.
PG  - 2039-45
LID - 10.3899/jrheum.100180 [doi]
AB  - OBJECTIVE: Cytokines are central regulators of the immune response but the 
      workings of this complex network in systemic lupus erythematosus (SLE) are not 
      fully understood. We investigated a range of inflammatory and immune-modulating 
      cytokines to determine their value as biomarkers for disease subsets in SLE. 
      METHODS: This was a cross-sectional study in 102 patients with SLE (87% women, 
      disease duration 10.6 yrs). Circulating concentrations of interleukin 1beta (IL-1beta), 
      IL-4, IL-6, IL-10, IL-12, IL-17, monocyte chemotactic protein 1 (MCP-1), 
      macrophage inflammatory protein 1 (MIP-1alpha), MIP-1beta, interferon-gamma (IFN-gamma), tumor 
      necrosis factor-alpha (TNF-alpha), and total transforming growth factor-beta1 (TGF-beta1) were 
      related to disease activity (SLE Disease Activity Index; SLEDAI), lymphocyte 
      subsets, autoantibody levels, accrued damage (Systemic Lupus International 
      Collaborating Clinics/ACR Damage Index; SDI), and concomitant treatment. RESULTS: 
      Patients with SLE had lower levels of TGF-beta1 (p = 0.01) and IL-1beta (p = 0.0004) 
      compared to controls. TGF-beta1 levels were lower in patients with SLEDAI scores 
      1-10 and SDI > 3; and were correlated with CD4+, CD8+, and natural killer cell 
      counts; and were independent of steroid or cytotoxic drug use. Treatment with 
      cardiovascular drugs was associated with lower IL-12 levels. No consistent 
      disease associations existed for the other cytokines investigated. CONCLUSION: 
      Lower TGF-beta1 was the most consistent cytokine abnormality in patients with SLE. 
      The associations with disease activity, lymphocyte subsets, and damage suggest 
      that TGF-beta1 may be a therapeutic target of interest in SLE.
FAU - Becker-Merok, Andrea
AU  - Becker-Merok A
AD  - Department of Rheumatology, Institute of Clinical Medicine, University of Tromso, 
      Tromso, Norway.
FAU - Eilertsen, Gro Ostli
AU  - Eilertsen GO
FAU - Nossent, Johannes C
AU  - Nossent JC
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100803
PL  - Canada
TA  - J Rheumatol
JT  - The Journal of rheumatology
JID - 7501984
RN  - 0 (Biomarkers)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Interleukins)
RN  - 0 (Macrophage Inflammatory Proteins)
RN  - 0 (Transforming Growth Factor beta)
RN  - 0 (Transforming Growth Factor beta1)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
CIN - J Rheumatol. 2010 Oct;37(10):1983-5. PMID: 20889608
MH  - Adult
MH  - Aged
MH  - Biomarkers/blood
MH  - Chemokine CCL2/blood/immunology
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Interferon-gamma/blood/immunology
MH  - Interleukins/blood/immunology
MH  - *Lupus Erythematosus, Systemic/blood/immunology/physiopathology
MH  - Macrophage Inflammatory Proteins/blood/immunology
MH  - Middle Aged
MH  - Transforming Growth Factor beta/*blood/*immunology
MH  - Transforming Growth Factor beta1/blood/immunology
EDAT- 2010/08/05 06:00
MHDA- 2011/02/15 06:00
CRDT- 2010/08/05 06:00
PHST- 2010/08/05 06:00 [entrez]
PHST- 2010/08/05 06:00 [pubmed]
PHST- 2011/02/15 06:00 [medline]
AID - jrheum.100180 [pii]
AID - 10.3899/jrheum.100180 [doi]
PST - ppublish
SO  - J Rheumatol. 2010 Oct;37(10):2039-45. doi: 10.3899/jrheum.100180. Epub 2010 Aug 
      3.